ESI-GROUP
21.10.2021 08:02:16 CEST | Business Wire | Press release
Regulatory News:
Gaïa Research, a service of EthiFinance and a major player in the field of ESG rating (environment, social and governance) of French mid-sized listed companies, has awarded ESI Group (Paris:ESI), a global player in virtual prototyping, committed to a cleaner, safer, and more productive industry, the first Gaïa 2021 prize in the category of mid-cap companies with annual revenues under €150 million.
This award received during the ceremony held on October 19th , 2021 in Paris, illustrates the efforts made by the Group to continuously improve its CSR commitments (social, societal, and environmental).
2021 was shaped by several significant actions for ESI Group, both within its governance, its environmental commitments, some in collaboration with Reforest'Action , and above all, with initiatives dedicated to its employees.
Particularly shaken by the Covid-19 health crisis, the work-life balance was a field of action for ESI Group, which employs 1,200 people in about 20 countries. In this context, the Group has introduced a "No-Meeting Day ": one-day per week dedicated to restoring the importance of taking time, without meetings, enabling employees to work differently. While reducing the stress and pressure caused by overloaded agendas, this format increases the concentration and productivity of teams.
"We are delighted with this new distinction from Gaïa Research. In 2021, ESI succeeded in optimizing its ESG commitment on all areas. The pandemic has disrupted the lives of our teams as well as our work habits. With the ‘No-Meeting Day’, we wanted to offer an initiative that would give our employees the opportunity to break the rhythm which could sometimes be counterproductive and allow them to thrive in their missions. We also worked for the Planet by helping reforestation, strengthened the independence of our governance and contributed to the decarbonization of the industry through our solutions. All this would not have been possible without the contribution of all our teams, who, in addition to being expert and recognized, reflect diversity. This is a real source of pride for all of us!" declared Corinne Romefort-Régnier , ESI Group's Governance Director.
“We want to be a vector of progress. The companies monitored by the Gaïa Research teams are growing companies with strong development ambitions. Our objective, in addition to supporting financial players in their responsible investment approach, is also to prepare companies for the new expectations of their stakeholders in terms of environmental, social and governance issues," says Emmanuel de La Ville of Gaïa Research. "Our evaluations allow investors to identify the most transparent and efficient companies in terms of CSR."
Methodology:
Since 2009, Gaïa Research has been conducting an annual data collection campaign covering most of the SMEs listed in France. Based on this information, companies are rated on their level of transparency and performance. The ratings are based on 174 criteria (economic, governance, human capital, environment and stakeholders) and are used by leading management companies in their management process and investment decisions. Since its creation, this index has outperformed the CAC 40 and the CAC Mid & Small every year.
About ESI Group
Founded in 1973, ESI Group envisions a world where Industry commits to bold outcomes, addressing high stakes concerns - environmental impact, safety & comfort for consumers and workers, adaptable and sustainable business models. ESI provides reliable and customized solutions anchored on predictive physics modeling and virtual prototyping expertise to allow industries to make the right decisions at the right time, while managing their complexity. Acting principally in automotive & land transportation, aerospace, defense & naval, energy and heavy industry, ESI is present in more than 20 countries, employs 1200 people around the world and reported 2020 sales of €132.6 million. ESI is headquartered in France and is listed on compartment B of Euronext Paris.
For further information, go to www.esi-group.com .
Follow ESI
LinkedIn
| Facebook
| Twitter
| YouTube
About Gaia Research, EthiFinance and Qivalio
Gaia Research is an EthiFinance service, a subsidiary of Qivalio, a European rating, research and consulting group dedicated to sustainable finance and development. The Group provides solutions to investors, companies and organizations to meet the challenges of financing and environmental and societal transformations. Created in 2017, Qivalio is the result of the merger between Spread Research and EthiFinance, French financial and extra-financial rating agencies founded in 2004. The group's purpose is to work towards the transformation of finance and the real economy for a more sustainable society, by promoting enlightened and responsible decision-making.
Qivalio serves a portfolio of leading international clients under Spread Research (independent credit research), Qivalio Ratings (financial rating agency), Qivalio Analytics (risk modelling) and EthiFinance (extra-financial rating and advisory agency) brands.
For further information: www.ethifinance.com www.qivalio.com
View source version on businesswire.com: https://www.businesswire.com/news/home/20211020006161/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
NTT DOCOMO BUSINESS and Chile’s State-owned Copper Company CODELCO Launch a Study and Proof of Concept Aimed at Improving the Efficiency of Remote Copper Mine Operations Using IOWN® APN6.8.2026 06:30:00 CEST | Press release
NTT DOCOMO BUSINESS, Inc. (formerly NTT Communications Corporation) has launched a study and proof of concept jointly with Corporación Nacional del Cobre de Chile (CODELCO) to progress remote operations at CODELCO’s copper mines using an IOWN® All-Photonics Network (APN).1 This initiative is part of a research project commissioned by Japan’s Ministry of Internal Affairs and Communications.2 This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260806845222/en/ Conceptual Diagram of the Demonstration To address operational challenges faced by CODELCO’s copper mines, the initiative will connect a copper mine and a remote operations center—approximately 1,500 km apart—via an IOWN APN. It will assess the feasibility of remotely operating heavy machinery using high-capacity, low-latency communication links, enhancing monitoring operations through high-definition video, and implementing a remote operations model. 1. Background Chile is o
FPT Named an OpenAI Select Partner6.8.2026 02:00:00 CEST | Press release
Global IT corporation FPT today announced that it has been named an OpenAI Select Partner within the OpenAI Partner Network. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260805503787/en/ FPT Named an OpenAI Select Partner The OpenAI Partner Network is a global program for partners to build, sell, and deliver AI solutions with OpenAI. It brings together partners with deep industry expertise, delivery capabilities, and customer relationships while equipping them with resources, enablement, and support to help enterprises adopt OpenAI frontier models and products and turn them into measurable impact. As an OpenAI Select Partner, FPT will continue working with OpenAI to help organizations build, deploy, and scale AI solutions responsibly and effectively. This work will help organizations get more useful work from every token and stronger performance per dollar with GPT‑5.6, while using ChatGPT Work to turn ambitious goals into
U.S. FDA Approves Takeda’s ORZEYFUL™ (oveporexton), the First and Only Medicine to Treat the Underlying Cause of Narcolepsy Type 16.8.2026 00:10:00 CEST | Press release
Adults Taking ORZEYFUL Experienced Significant and Meaningful Improvements Across the Full Range of Symptoms of Narcolepsy Type 1 (NT1) in Clinical Trials Compared to Those on Placebo As a First-in-Class Orexin Treatment, ORZEYFUL has the Potential to Redefine NT1 Care Beyond Individual Symptoms Takeda is Advancing U.S. Launch Preparations and Expects to Make ORZEYFUL Available Following Completion of the Drug Enforcement Administration (DEA) Scheduling Process Takeda (TSE:4502/NYSE:TAK) announced that the U.S. Food and Drug Administration (FDA) approved ORZEYFUL™ (oveporexton), an oral orexin receptor 2 (OX2R) agonist, for the treatment of narcolepsy type 1 (NT1, narcolepsy with cataplexy) in adults.* The persistent 24-hour nature of NT1 is driven by orexin deficiency and can severely impact people’s lives. As a first-in-class orexin treatment, ORZEYFUL is the only medicine indicated in the U.S. to treat the disease holistically rather than individual symptoms. “The FDA approval of OR
Compass Pathways Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)5.8.2026 22:30:00 CEST | Press release
Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to unlocking urgently needed new treatment options in mental health care, announced today that Compass granted equity awards under the Compass Pathways plc 2026 Inducement Plan to fourteen newly hired non-executive employees. The equity awards were granted on August 3, 2026 and consisted of options to purchase an aggregate of 139,355 shares and restricted share units or, in the case of employees in the United Kingdom nominal cost options, covering an aggregate of 66,300 shares. The options have an exercise price per share equal to $11.25, the closing price of the Company’s American Depositary Shares on the Nasdaq Global Select Market on the grant date, and will vest over a four-year period with 25% vesting on the first anniversary of the date of the grant and the remaining 75% vesting in equal monthly installments over the three-year period thereafter, subject to each employee’s continued employment. The restricted
Clinilabs Announces Medical Leadership Appointments5.8.2026 16:05:00 CEST | Press release
Bob Dagher, M.D., Named Chief Medical Officer and Waqar Ahmed Siddiqui, M.D., Named Principal Investigator Clinilabs (“Clinilabs LLC”), a global, full-service contract research organization (CRO) specializing in central nervous system (CNS) drug and device development, today announced the appointments of Bob Dagher, M.D., as Chief Medical Officer and Waqar Ahmed Siddiqui, M.D., as Principal Investigator of the Company’s Eatontown, New Jersey Clinical Research Unit (CRU). Dr. Dagher will provide strategic and medical leadership across the organization, while Dr. Siddiqui will lead the execution of research projects at the Company’s CRU. Together, they will support the design, development, and execution of clinical programs for pharmaceutical, biotechnology, and medical device sponsors advancing innovative therapies for psychiatric, neurological, substance use, and rare CNS disorders. “Clinilabs has earned the trust of sponsors by combining deep scientific expertise, medical leadership,
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
